RecruitingAsthma AcuteCOPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Sponsor: Connect Biopharm LLC
You may qualify if…
- ✓ Body weight of ≥40 kg and BMI ≤45 kg/m2 at SV1a.
- ✓ Physician-diagnosed asthma
- ✓ Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.
- ✓ Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids.
- ✓ Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
- ✓ Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.
- ✓ Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation.
- ✓ Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.
You may not qualify if…
- ✕ Regular use of immunosuppressive medication.
- ✕ Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.
- ✕ Current or former smoker, with a smoking history of ≥5 pack-years if \<30 years old or ≥10 pack-years if ≥30 years old
- ✕ COPD and other clinically significant pulmonary disease other than asthma.
- ✕ Known or suspected history of immunosuppression.
- ✕ History of known immunodeficiency disorder or hepatitis B or C.
- ✕ History of alcohol abuse and/or drug abuse.
- ✕ Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other malignancies treated with apparent success with curative therapy.
Where it's recruiting
Florida
Miami
Source: ClinicalTrials.gov · NCT07705737 · last updated 2026-08-27